Revlimid

Pronunciation[edit | edit source]

REV-lih-mid

Lenalidomide

Summary[edit | edit source]

A drug that is similar to thalidomide, and is used to treat multiple myeloma and certain types of anemia.
It is also used to treat mantle cell lymphoma that has come back or has not gotten better after other treatment.
It is being studied in the treatment of other conditions and types of cancer.
Revlimid may help the immune system kill abnormal blood cells or cancer cells.
It may also prevent the growth of new blood vessels that tumors need to grow.
It is a type of antiangiogenesis agent and a type of immunomodulating agent.
Also called CC-5013 and lenalidomide.

FDA warning[edit | edit source]

Lenalidomide, a thalidomide analogue, caused limb abnormalities in a developmental monkey study similar to birth defects caused by thalidomide in humans.
If lenalidomide is used during pregnancy, it may cause birth defects or embryo-fetal death.
Pregnancy must be excluded before start of treatment. Prevent pregnancy during treatment by the use of two reliable methods of contraception.
Revlimid is available only through a restricted distribution program, called the Revlemid REMS® program

Indications[edit | edit source]

Revlimid is a thalidomide analogue indicated for the treatment of adult patients with:
Multiple myeloma (MM), in combination with dexamethasone.
MM, as maintenance following autologous hematopoietic stem cell transplantation (auto-HSCT).
Transfusion-dependent anemia due to low- or intermediate-1-risk myelodysplastic syndromes (MDS) associated with a deletion 5q abnormality with or without additional cytogenetic abnormalities.
Mantle cell lymphoma (MCL) whose disease has relapsed or progressed after two prior therapies, one of which included bortezomib.
Previously treated follicular lymphoma (FL), in combination with a rituximab product.
Previously treated marginal zone lymphoma (MZL), in combination with a rituximab product.

Lenalidomide ball-and-stick

Mechanism of action[edit | edit source]

Lenalidomide is an analogue of thalidomide with immunomodulatory, antiangiogenic, and antineoplastic properties. Cellular activities of lenalidomide are mediated through its target cereblon, a component of a cullin ring E3 ubiquitin ligase enzyme complex.

In vitro actions[edit | edit source]

In vitro, in the presence of drug, substrate proteins (including Aiolos, Ikaros, and CK1α) are targeted for ubiquitination and subsequent degradation leading to direct cytotoxic and immunomodulatory effects.
Lenalidomide inhibits proliferation and induces apoptosis of certain hematopoietic tumor cells including MM, mantle cell lymphoma, and del (5q) myelodysplastic syndromes, follicular lymphoma and marginal zone lymphoma
in vitro Lenalidomide causes a delay in tumor growth in some

in vivo[edit | edit source]

nonclinical hematopoietic tumor models including MM.
Immunomodulatory properties of lenalidomide include increased number and activation of T cells and natural killer (NK) cells leading to direct and enhanced antibody-dependent cell-mediated cytotoxicity (ADCC) via increased secretion of interleukin-2 and interferon-gamma, increased numbers of NKT cells, and inhibition of pro-inflammatory cytokines (e.g., TNF-α and IL-6) by monocytes.
In MM cells, the combination of lenalidomide and dexamethasone synergizes the inhibition of cell proliferation and the induction of apoptosis. The combination of lenalidomide and rituximab increases ADCC and direct tumor apoptosis in follicular lymphoma cells and increases ADCC in marginal zone lymphoma cells compared to rituximab alone in vitro.

Limitations of Use[edit | edit source]

REVLIMID is not indicated and is not recommended for the treatment of patients with chronic lymphocytic leukemia (CLL) outside of controlled clinical trials.

Dosage[edit | edit source]

Multiple myeloma combination therapy: 25 mg once daily orally on Days 1-21 of repeated 28-day cycles.
Multiple myeloma maintenance therapy following auto-HSCT: 10 mg once daily continuously on Days 1-28 of repeated 28-day cycles.
Myelodysplastic syndrome: 10 mg once daily.
Mantle cell leukemia: 25 mg once daily orally on Days 1-21 of repeated 28-day cycles.
Follicular lymphoma or marginal zone lymphoma: 20 mg once daily orally on Days 1-21 of repeated 28-day cycles for up to 12 cycles.
Renal impairment: Adjust starting dose based on the creatinine clearance value.

Dosage forms[edit | edit source]

Capsules: 2.5 mg, 5 mg, 10 mg, 15 mg, 20 mg, and 25 mg.

Contraindications[edit | edit source]

Pregnancy
Demonstrated severe hypersensitivity to lenalidomide.

Side effects[edit | edit source]

Side effects vary based on the indication as noted below:

Multiple myeloma: Most common adverse reactions (≥20%) include diarrhea, fatigue, anemia, constipation, neutropenia, leukopenia, peripheral edema, insomnia, muscle cramp/spasms, abdominal pain, back pain, nausea, asthenia, pyrexia, upper respiratory tract infection, bronchitis, nasopharyngitis, gastroenteritis, cough, rash, dyspnea, dizziness, decreased appetite, thrombocytopenia, and tremor.
Myelodyspastic syndrome: Most common adverse reactions (>15%) include thrombocytopenia, neutropenia, diarrhea, pruritus, rash, fatigue, constipation, nausea, nasopharyngitis, arthralgia, pyrexia, back pain, peripheral edema, cough, dizziness, headache, muscle cramp, dyspnea, pharyngitis, [[and epistaxis.
Non-Hodgkin's lymphoma (NHL: MCL, FL or MZL): Most common adverse reactions (≥15%) included neutropenia, thrombocytopenia, anemia, leukopenia, diarrhea, constipation, nausea, fatigue, pyrexia, cough, upper respiratory tract infection, and rash.

History[edit | edit source]

Lenalidomide was first approved for medical use in the United States in 2005 by the US FDA.

Cost[edit | edit source]

Lenalidomide costs US$163,381 per year for the average person in the United States as of 2012.

Revlimid Resources
Need Help Finding a Doctor? Need help finding a doctor or specialist anywhere in the world? Explore our world directory. WikiMD's DocFinder can assist you in locating millions of physicians.	Medical Knowledge Access the latest research - Most recent articles Ongoing trials.